Source:http://linkedlifedata.com/resource/pubmed/id/18412022
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2008-4-16
|
pubmed:abstractText |
The aim of this study was to evaluate the cancer chemopreventive potential of the widely prescribed drug tibolone (17alpha-ethynyl-7alpha-methyl-5(10)-estren-3-one, CAS 5630-53-5) and its main metabolites, 17alpha-ethynyl-7alpha-methyl-4-estren-3-one (CAS 1162-60-3), 17alpha-ethynyl-7alpha-methyl-5(10)-estrene-3alpha,17beta-diol (CAS 100239-44-9) and 17alpha-ethynyl-7alpha-methyl-5(10)-estrene-3beta,17beta-diol (CAS 100239-45-0), by studying their anti-tumor-promoting activity. To this aim the test compounds were submitted to the short term in vitro assay for the inhibition of Epstein-Barr virus early antigen (EBV-EA) activation induced by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) as a primary screening for anti-tumor promoters. All the compounds showed high inhibitory activity and low cytotoxicity as compared to literature data. To extend the study to an animal model, tibolone and its 3alpha-hydroxy metabolite (CAS 100239-44-9) were also assayed in the in vivo two-stage on mouse skin carcinogenesis test, exhibiting significant inhibitory effects on TPA promoted mouse skin papillomas formation. A comparison with literature data indicated them as more potent compounds than other steroids previously studied such as digitoxigenin, cortisone, hydrocortisone, and prednisolone.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anticarcinogenic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Carcinogens,
http://linkedlifedata.com/resource/pubmed/chemical/Epstein-Barr Virus Nuclear Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Norpregnenes,
http://linkedlifedata.com/resource/pubmed/chemical/Selective Estrogen Receptor...,
http://linkedlifedata.com/resource/pubmed/chemical/Tetradecanoylphorbol Acetate,
http://linkedlifedata.com/resource/pubmed/chemical/tibolone
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0004-4172
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
58
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
86-90
|
pubmed:meshHeading |
pubmed-meshheading:18412022-Animals,
pubmed-meshheading:18412022-Anticarcinogenic Agents,
pubmed-meshheading:18412022-Carcinogens,
pubmed-meshheading:18412022-Cell Line, Tumor,
pubmed-meshheading:18412022-Epstein-Barr Virus Nuclear Antigens,
pubmed-meshheading:18412022-Female,
pubmed-meshheading:18412022-Mice,
pubmed-meshheading:18412022-Norpregnenes,
pubmed-meshheading:18412022-Papilloma,
pubmed-meshheading:18412022-Selective Estrogen Receptor Modulators,
pubmed-meshheading:18412022-Skin Neoplasms,
pubmed-meshheading:18412022-Tetradecanoylphorbol Acetate
|
pubmed:year |
2008
|
pubmed:articleTitle |
Anti-tumor-Promoting activity of tibolone and its metabolites.
|
pubmed:affiliation |
Dipartimento di Chimica, Biochimica e Biotecnologie per la Medicina, Università di Milano, Milan, Italy. diego.colombo@unimi.it
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|